News room
Technophage has been listed as ‘One of FT1000’s Fastest-Growing Companies in Europe’
The continued growth of Technophage from a small biotech into a clinical-stage biopharma has resulted in the company making the Financial Times'...
Technophage granted with the ‘COTEC Innovative Status 2022′
Technophage is proud to announce that it has recently been granted with the ‘COTEC Innovative Status 2022’. COTEC Portugal is the main Portuguese...
Technophage is hiring an Intellectual Property Manager
TechnoPhage is currently looking for a new Intellectual Property Manager with a degree in life sciences technical field, postgraduate studies in IP...
TechnoPhage announces signing of a PRR Grant Agreement with the Portuguese Government
Technophage, together with partners LX Bio, VectorB2B and FFUL is pleased to announce the signing of a new PRR Grant Agreement with the Portuguese...
TechnoPhage Announces First Clinical Safety Results with Innovative Biological Product TP-102
TechnoPhage is proud to announce that the first part of the Phase I/IIa Clinical Trial with TP-102 (REVERSE study) has been completed. The study...